181 related articles for article (PubMed ID: 10226546)
1. Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells.
Lei W; Mayotte JE; Levitt ML
Anticancer Res; 1999; 19(1A):221-8. PubMed ID: 10226546
[TBL] [Abstract][Full Text] [Related]
2. EGF-dependent and independent programmed cell death pathways in NCI-H596 nonsmall cell lung cancer cells.
Lei W; Mayotte JE; Levitt ML
Biochem Biophys Res Commun; 1998 Apr; 245(3):939-45. PubMed ID: 9588219
[TBL] [Abstract][Full Text] [Related]
3. Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin.
Zhang L; Hung MC
Oncogene; 1996 Feb; 12(3):571-6. PubMed ID: 8637714
[TBL] [Abstract][Full Text] [Related]
4. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
5. Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells.
Lee LT; Huang YT; Hwang JJ; Lee PP; Ke FC; Nair MP; Kanadaswam C; Lee MT
Anticancer Res; 2002; 22(3):1615-27. PubMed ID: 12168845
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.
Suzuki T; Fujii A; Ohya J; Nakamura H; Fujita F; Koike M; Fujita M
Cancer Sci; 2009 Aug; 100(8):1526-31. PubMed ID: 19459856
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells.
Tsai CM; Levitzki A; Wu LH; Chang KT; Cheng CC; Gazit A; Perng RP
Cancer Res; 1996 Mar; 56(5):1068-74. PubMed ID: 8640763
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer.
Onn A; Isobe T; Wu W; Itasaka S; Shintani T; Shibuya K; Kenji Y; O'reilly MS; Fidler IJ; Herbst RS
Clin Cancer Res; 2004 Dec; 10(24):8613-9. PubMed ID: 15623645
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation.
Luppi F; Longo AM; de Boer WI; Rabe KF; Hiemstra PS
Lung Cancer; 2007 Apr; 56(1):25-33. PubMed ID: 17175059
[TBL] [Abstract][Full Text] [Related]
10. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells.
Song L; Turkson J; Karras JG; Jove R; Haura EB
Oncogene; 2003 Jul; 22(27):4150-65. PubMed ID: 12833138
[TBL] [Abstract][Full Text] [Related]
11. Preferential inhibition of glioblastoma cells with wild-type epidermal growth factor receptors by a novel tyrosine kinase inhibitor ethyl-2,5-dihydroxycinnamate.
Han Y; Caday CG; Umezawa K; Nanda A
Oncol Res; 1997; 9(11-12):581-7. PubMed ID: 9563005
[TBL] [Abstract][Full Text] [Related]
12. Effect of epidermal growth factor receptor inhibitor alone and in combination with cisplatin on growth of vulvar cancer cells.
Kim SH; Song YC; Kim SH; Jo H; Song YS
Ann N Y Acad Sci; 2009 Aug; 1171():642-8. PubMed ID: 19723115
[TBL] [Abstract][Full Text] [Related]
13. Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors.
Han Y; Caday CG; Nanda A; Cavenee WK; Huang HJ
Cancer Res; 1996 Sep; 56(17):3859-61. PubMed ID: 8752145
[TBL] [Abstract][Full Text] [Related]
14. Small cell lung cancer cells express EGFR and tyrosine phosphorylation of EGFR is inhibited by gefitinib ("Iressa", ZD1839).
Tanno S; Ohsaki Y; Nakanishi K; Toyoshima E; Kikuchi K
Oncol Rep; 2004 Nov; 12(5):1053-7. PubMed ID: 15492792
[TBL] [Abstract][Full Text] [Related]
15. TGF-alpha-driven tumor growth is inhibited by an EGF receptor tyrosine kinase inhibitor.
El-Obeid A; Hesselager G; Westermark B; Nistér M
Biochem Biophys Res Commun; 2002 Jan; 290(1):349-58. PubMed ID: 11779176
[TBL] [Abstract][Full Text] [Related]
16. Mitogen-activated protein kinase phosphatase-1 modulated JNK activation is critical for apoptosis induced by inhibitor of epidermal growth factor receptor-tyrosine kinase.
Takeuchi K; Shin-ya T; Nishio K; Ito F
FEBS J; 2009 Mar; 276(5):1255-65. PubMed ID: 19175673
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of neuropeptide-stimulated tyrosine phosphorylation and tyrosine kinase activity stimulates apoptosis in small cell lung cancer cells.
Tallett A; Chilvers ER; Hannah S; Dransfield I; Lawson MF; Haslett C; Sethi T
Cancer Res; 1996 Sep; 56(18):4255-63. PubMed ID: 8797601
[TBL] [Abstract][Full Text] [Related]
18. The inhibition of the pemetrexed-activated MAPK pathway via sorafenib is involved in the synergistic mechanism of sorafenib subsequent potentiation of pemetrexed cytotoxicity in EGFR TKI-resistant cell lines.
Jiang Y; Li C; Ma Y; Chen J; Li Y; Chen L
Clin Lab; 2012; 58(5-6):551-61. PubMed ID: 22783588
[TBL] [Abstract][Full Text] [Related]
19. Modulation of the cytotoxic activity of tumor necrosis factor by protein tyrosine kinase and protein tyrosine phosphatase inhibitors.
Mishra S; Mathur R; Hamburger AW
Lymphokine Cytokine Res; 1994 Apr; 13(2):77-83. PubMed ID: 8061118
[TBL] [Abstract][Full Text] [Related]
20. Alterations of the cytoskeletal organization in tumor cell lines by a cardiotonic drug, vesnarinone, through protein tyrosine phosphorylation.
Yoshinaka Y; Katoh I; Kyushiki H; Sakamoto Y
Exp Cell Res; 1995 Jul; 219(1):21-8. PubMed ID: 7543053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
